Ki-67 + SSRT2A NEN Pilot Study featuring Mindpeak GmbH
We’re excited to share that our AI-powered pathology algorithms were an integral part in a pioneering study on AI-assisted SSRT2A and Ki-67 readout in neuroendocrine neoplasms (NEN). T
he work was recently presented at the 22nd ENETS Conference in Krakow, Poland by PD Dr. med. Daniel Kaemmerer.
The study demonstrated that Mindpeak’s AI delivers clinical-grade performance for IHC scoring in NEN:
✅ 92% agreement with manual evaluation for SSTR2A (pos. vs. neg.)
✅ High interobserver reliability for Ki-67 (Krippendorff's α = 0.83)
✅ System usability score (SUS) of 75 (Grade B)
This proof-of-concept marks another step forward on our mission to bring AI-assisted diagnostics into broad routine pathology, supporting pathologists for more efficient, accurate and reproducible diagnoses.
“AI is not replacing pathologists—it’s empowering them!” summarizes Dr. Kämmerer.
"This study confirmed that AI-powered digital pathology is no longer a vision for the future—it’s a reality today. With high accuracy and usability, Mindpeak’s AI software can support pathologists in making faster, more reliable diagnoses."
A huge thank you to PD Dr. med. Daniel Kaemmerer and the research team for pioneering AI use in neuroendocrine neoplasms.
